Short term cardioselective beta-blocker use safe in COPD

Clinical question: 
Can I safely prescribe cardioselective beta-blockers for individuals with chronic obstructive pulmonary disease (COPD)?
Bottom line: 
In patients with COPD, cardioselective beta-blockers given as a single dose or for longer duration produce no change in FEV1 or respiratory symptoms compared to placebo, and do not affect the FEV1 treatment response to beta-2 agonists.
Caveat: 
The mean duration of the studies included in the meta-analysis was only 3.7 weeks (range 2 days to 12 weeks). Most of the studies were small.
Context: 
Beta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary heart disease. Traditionally these drugs have been considered contraindicated in patients with COPD.
Review CD#: 
CD003566
PEARLS No: 
6
Date: 
July, 2007
Authored by: 
Brian R McAvoy
File: